Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


Positive Results from First Preclinical in-vivo Studies of Affimer Therapeutics

publication date: Oct 7, 2016
author/source: Avacta Life Sciences

Affimer PD-L1 inhibitor significantly reduces tumour growth in mouse model

AvactaAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules. The results meaningfully de-risk the development of the technology as a therapeutic platform; demonstrating that Affimer molecules possess good drug-like properties in terms of efficacy, serum half-life and tolerability.

  • Good pharmacokinetic properties observed
  • Affimer molecules well tolerated at all dosing levels
  • No adverse effects observed
  • Confirms the potential of the Affimer technology as a therapeutic platform

Two parallel in-vivo pre-clinical studies have been completed. The first, a pharmacokinetics study looking at both human and mouse PD-L1 Affimer inhibitors1engineered as Fc fusions2, showed that Affimer molecules have good in-vivo serum half-lives and are well tolerated at the clinically relevant doses used in the study. 

The second was an efficacy study using a mouse PD-L1 specific Affimer molecule in a syngeneic tumour model3. In this study the Affimer PD-L1 inhibitor produced a statistically significant reduction in tumour growth demonstrating the bioavailability and functionality of the Affimer molecule in tumours in-vivo. No adverse effects were observed.

Alastair Smith, Avacta Group Chief Executive commented: “These results demonstrate that Affimer molecules possess good in-vivo drug-like properties in terms of efficacy, serum half-life and tolerability which is a hugely important milestone in the development and de-risking of the technology as a therapeutic platform. From the initial screening process for the Affimer binders we have been able to rapidly progress to evaluating them in in-vivo models, highlighting another major advantage of the technology. We are very encouraged by these initial positive results and will continue to focus on developing both our internal and partnered therapeutic programs towards clinical validation.”

more about avacta

more news from avacta

Watch the video , below, about Affimer technology and therapeutic applications


If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Exhibitions & Events

Media Partner